$BBIO
5 articles on $BBIO
- $INOBullish
KXCO's FDA Ontology Ranked INO-3107 First. Inovio Hit Over 300% After Hours.
KXCO's FDA ontology ranked INO-3107, from Inovio (INO), first of the FDA decisions due in the next 90 days, from 21 October 2026 to the decision. The FDA granted accelerated approval on 30 October; the news reached the market after the close. From its $0.60 close that day, Inovio traded as high as $2.71 after hours, up 351.7%, and closed 2 November at $1.89, up 215.0%. Both published research books closed ahead of XBI. On our radar: BBP-418 (BBIO), Bezuclastinib (COGT) and Relutrigine (PRAX).
Shayne Heffernan13 min - FDABullish
What the Round Table Is Predicting in Biotech Markets
Seventeen FDA decisions fall due between 30 October 2026 and 29 June 2027, and KXCO's Round Table has called every one. Its model portfolio holds the thirteen Nasdaq companies behind them, led by BridgeBio, Cogent Biosciences and Praxis, and was signed with ML-DSA-87 and anchored on chain before the FDA acts. The first test is Inovio's INO-3107 on 30 October.
Shayne Heffernan5 min - $NVDABullish
Week Ahead on Wall Street: CPI, Banks and Oil
September CPI lands on Wednesday after a Fed hike and a 10-year yield at its highest since 2002. JPMorgan, Goldman and Citi open bank earnings on Tuesday, ASML and TSMC report midweek, and Saudi pipeline attacks kept Brent at $104.72 on 9 October 2026, per CNBC. The KXCO AI Sector Ontology still shows contracted demand. This week ahead sets out the calendar, the three facts that would change the call, and why dips in the AI leaders remain buying opportunities.
Shayne Heffernan23 min - $NVDABullish
Weekly Market Outlook: Fed Minutes, Anthropic and OpenAI IPOs, Gold, Bitcoin, FX
The Fed raised rates in September and payrolls rose 29,000, per the Labor Department. This week the FOMC minutes, three Treasury auctions and a 10-year near 5.3 percent test that gap. Anthropic's IPO clock runs toward a 14 October investor day while OpenAI's chief executive says not 2026. Gold sits 26 percent below its record, bitcoin near $85,500, the dollar up three weeks running. Two knowledge graphs from KXCO's records map the IPO backers and the FDA board.
Shayne Heffernan25 min - $BBIOBullish
The FDA Calendar to April 2027: 5 Biotech Stocks From the KXCO Biotech Ontology
The KXCO Biotech Ontology's board carries 11 pending FDA filings, due by 23 April 2027. Ranked on approval standing, the top five are BridgeBio's BBP-418, Cogent's bezuclastinib, Belite Bio's tinlarebant, Novo Nordisk's CagriSema and BioMarin's vosoritide. Ranked on consensus upside, they are Cullinan, Savara, Intellia, Mineralys and Pharvaris. No name is on both lists. This report covers BridgeBio, Cogent, Mineralys, Pharvaris and Savara.
Shayne Heffernan23 min